Skip to main content
Clinical Trials/NCT04386512
NCT04386512
Completed
Not Applicable

Épidémiologie Clinique et caractéristiques Des Cas de Covid-19 Survenus Dans un Contexte de Lymphome Lors de la première Phase épidémique

Versailles Hospital1 site in 1 country89 target enrollmentMay 15, 2020
ConditionsCOVIDLymphoma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID
Sponsor
Versailles Hospital
Enrollment
89
Locations
1
Primary Endpoint
mortality
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The main objective of this retrospective clinical epidemiology study is to describe the characteristics of Covid-19 cases requiring hospitalization in adult patients with lymphomas during the initial phase of the epidemic (from 01/03/20 to 30/04/20).

The specific objectives are to estimate the frequency of severe forms of Covid-19 and those requiring intensive care hospitalisation, as well as the mortality related to the epidemic among the active file of patients followed for lymphoma at each study site, to investigate whether certain chemotherapy and/or immunotherapy treatments seem to be associated with severe forms or prolonged evolutions of Covid-19, to describe possible atypical clinical forms among the population of patients treated for lymphoma.

Translated with www.DeepL.com/Translator (free version)

Detailed Description

I Methods : * Multicentric retrospective observational epidemiological study based on the collection of data from patient records. * Selection of voluntary hospital sites in regions with excess mortality during the epidemic phase. * Systematic identification of Covid-19 cases from coding data (PMSI) from the medical information departments which will be compared with the numbers of patients followed for lymphoma in the haematology departments of each site during the 6 months preceding the epidemic, identified through the PMSI. * Establishment of an ad hoc CRF for cases only with collection of clinical data concerning lymphoma and Covid-19 and routine biological data: Cytopenia (and in particular depth of lymphopenia), hypogammaglobulinemia, inflammatory markers. * Estimated total number of sites: 10-15 and number of cases to be collected: 50-60. Translated with www.DeepL.com/Translator (free version)

Registry
clinicaltrials.gov
Start Date
May 15, 2020
End Date
July 15, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Versailles Hospital
Responsible Party
Principal Investigator
Principal Investigator

Caroline BESSON

investigator MD

Versailles Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients at least 18 years of age with lymphoma and a diagnosis of Covid-19 requiring hospitalization.
  • In order not to bias the data by excluding patients with adverse outcomes, we will also collect data from deceased patients.

Exclusion Criteria

  • Patients who refused to participate

Outcomes

Primary Outcomes

mortality

Time Frame: 2 months

transfer to ICU

Time Frame: 2 months

Study Sites (1)

Loading locations...

Similar Trials